Axsome Therapeutics, Inc.AXSMEarnings & Financial Report

Nasdaq · pharmaceutical industry

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

NextMar 31, 2026

Revenue

$171.0M

Gross Profit

N/A

Operating Profit

$-46.1M

Net Profit

$-47.2M

Gross Margin

N/A

Operating Margin

-27.0%

Net Margin

-27.6%

YoY Growth

63.2%

EPS

$-0.94

Financial Flow

Axsome Therapeutics, Inc. Q3 2025 Financial Summary

Axsome Therapeutics, Inc. reported revenue of $171.0M for Q3 2025, with a net profit of $-47.2M (-27.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$171.0M
Net Profit	$-47.2M
Gross Margin	N/A
Operating Margin	-27.0%
Report Period	Q3 2025

Axsome Therapeutics, Inc. Annual Revenue by Year

Axsome Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $385.7M).

Year	Annual Revenue
2024	$385.7M
2023	$270.6M
2022	$50.0M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$71.5M	$75.0M	$87.2M	$104.8M	$118.8M	$121.5M	$150.0M	$171.0M
YoY Growth	193.5%	-20.7%	86.7%	81.3%	66.0%	62.0%	72.1%	63.2%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$588.2M	$545.7M	$548.2M	$561.5M	$568.5M	$596.7M	$639.8M	$669.3M
Liabilities	$397.3M	$401.7M	$445.4M	$468.6M	$511.5M	$543.5M	$566.7M	$595.5M
Equity	$191.0M	$144.0M	$102.9M	$92.9M	$57.0M	$53.2M	$73.1M	$73.7M